文献速递乳腺癌消化系统肿瘤

以基因型为先的方法识别CDH1胚系变异与癌症表型的关联:欧洲遗传性肿瘤风险综合征参考网络的多中心研究

Genotype-first approach to identify associations between CDH1 germline variants and cancer phenotypes: a multicentre study by the European Reference Network on Genetic Tumour Risk Syndromes.
PubMed 文献 · Lancet Oncol · 2022-11-24

该多中心基因型为先研究纳入来自10国29个机构的854例携带398种罕见CDH1变异者及1021名亲属,比较致病/可能致病变异与意义未明错义变异者的癌症谱。结果显示,小叶乳腺癌与致病/可能致病变异关联最强(OR 12.39),弥漫型胃癌和胃癌亦呈正关联;意义未明错义变异未发现与这些表型正关联。以小叶乳腺癌为中心的扩展标准可提高检出灵敏度并保持高特异度。

要点

  • 携带CDH1致病/可能致病变异家族中小叶乳腺癌与变异正关联最强(OR 12.39)。
  • CDH1意义未明错义变异未发现与HDGC相关表型存在正关联。
  • 以小叶乳腺癌为中心的扩展标准较2020标准显著提高检出概率(AUC 0.92 vs 0.88)。

核心结论

  • CDH1致病/可能致病变异与HDGC相关表型(小叶乳腺癌、弥漫型胃癌和胃癌)呈正关联,而意义未明错义变异未发现与这些表型正关联。
  • CDH1致病/可能致病变异常见于不符合2020 HDGC标准的小叶乳腺癌家族,支持扩展以小叶乳腺癌为中心的标准。

研究设计与样本

  • 基因型为先研究,使用来自欧洲肿瘤风险综合征参考网络(ERN GENTURIS)10个成员国29个机构的854例携带398种罕见CDH1变异者及1021名亲属的回顾性诊断和临床数据。
  • 数据收集时间为2018年10月1日至2022年9月20日,变异按美国医学遗传学与基因组学学会/分子病理学协会CDH1指南(第2版)分类,家族按是否满足2015和2020 HDGC临床标准分组。
  • 采用Student t检验、Kruskal-Wallis检验、χ2检验和多变量逻辑回归分析基因型-表型关联,用等效性检验和Youden指数评估HDGC临床标准集性能,并用Z检验比较受试者工作特征曲线下面积。

主要发现

  • 在1971例表型(来自854例先证者和1021名1-93岁亲属)中,460例有胃和乳腺癌组织学资料。
  • CDH1截短致病/可能致病变异见于176/854(21%)家族,意义未明错义变异见于169/854(20%)家族。
  • 多变量逻辑回归比较携带致病/可能致病变异或意义未明错义变异家族中出现的表型,显示小叶乳腺癌与致病/可能致病变异正关联最强(比值比12.39 [95% CI 2.66-57.74],p=0.0014),其次为弥漫型胃癌(8.00 [2.18-29.39],p=0.0017)和胃癌(7.81 [2.03-29.96],p=0.0027)。
  • 176个携带致病/可能致病变异家族中136个(77%)符合2015 HDGC标准;剩余40个(23%)不符合2015标准家族中,11个符合2020 HDGC标准,18个仅有小叶乳腺癌或小叶乳腺癌加胃癌但不符合2020标准。
  • 未发现特定CDH1变异特异性地易感小叶乳腺癌,尽管12/176(7%)致病/可能致病变异携带家族仅有小叶乳腺癌。

关键数值与推荐

  • 多变量逻辑回归中,小叶乳腺癌与致病/可能致病变异正关联:比值比12.39(95% CI 2.66-57.74),p=0.0014。
  • 弥漫型胃癌与致病/可能致病变异正关联:比值比8.00(95% CI 2.18-29.39),p=0.0017。
  • 胃癌与致病/可能致病变异正关联:比值比7.81(95% CI 2.03-29.96),p=0.0027。
  • 小叶乳腺癌扩展标准与2020标准比较:AUC 0.92 vs 0.88;Z评分3.54;p=0.0004。

临床怎么用

  • 作者认为,CDH1致病/可能致病变异常见于不符合2020 HDGC标准的小叶乳腺癌家族,支持扩展以小叶乳腺癌为中心的标准。
  • 作者报告加入三条新的以小叶乳腺癌为中心的标准提高了检测灵敏度并保持高特异度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Truncating pathogenic or likely pathogenic variants of CDH1 cause hereditary diffuse gastric cancer (HDGC), a tumour risk syndrome that predisposes carrier individuals to diffuse gastric and lobular breast cancer. Rare CDH1 missense variants are often classified as variants of unknown significance. We conducted a genotype-phenotype analysis in families carrying rare CDH1 variants, comparing cancer spectrum in carriers of pathogenic or likely pathogenic variants (PV/LPV; analysed jointly) or missense variants of unknown significance, assessing the frequency of families with lobular breast cancer among PV/LPV carrier families, and testing the performance of lobular breast cancer-expanded criteria for CDH1 testing. METHODS: This genotype-first study used retrospective diagnostic and clinical data from 854 carriers of 398 rare CDH1 variants and 1021 relatives, irrespective of HDGC clinical criteria, from 29 institutions in ten member-countries of the European Reference Network on Tumour Risk Syndromes (ERN GENTURIS). Data were collected from Oct 1, 2018, to Sept 20, 2022. Variants were classified by molecular type and clinical actionability with the American College of Medical Genetics and Association for Molecular Pathology CDH1 guidelines (version 2). Families were categorised by whether they fulfilled the 2015 and 2020 HDGC clinical criteria. Genotype-phenotype associations were analysed by Student's t test, Kruskal-Wallis, χ2, and multivariable logistic regression models. Performance of HDGC clinical criteria sets were assessed with an equivalence test and Youden index, and the areas under the receiver operating characteristic curves were compared by Z test. FINDINGS: From 1971 phenotypes (contributed by 854 probands and 1021 relatives aged 1-93 years), 460 had gastric and breast cancer histology available. CDH1 truncating PV/LPVs occurred in 176 (21%) of 854 families and missense variants of unknown significance in 169 (20%) families. Multivariable logistic regression comparing phenotypes occurring in families carrying PV/LPVs or missense variants of unknown significance showed that lobular breast cancer had the greatest positive association with the presence of PV/LPVs (odds ratio 12·39 [95% CI 2·66-57·74], p=0·0014), followed by diffuse gastric cancer (8·00 [2·18-29·39], p=0·0017) and gastric cancer (7·81 [2·03-29·96], p=0·0027). 136 (77%) of 176 families carrying PV/LPVs fulfilled the 2015 HDGC criteria. Of the remaining 40 (23%) families, who did not fulfil the 2015 criteria, 11 fulfilled the 2020 HDGC criteria, and 18 had lobular breast cancer only or lobular breast cancer and gastric cancer, but did not meet the 2020 criteria. No specific CDH1 variant was found to predispose individuals specifically to lobular breast cancer, although 12 (7%) of 176 PV/LPV carrier families had lobular breast cancer only. Addition of three new lobular breast cancer-centred criteria improved testing sensitivity while retaining high specificity. The probability of finding CDH1 PV/LPVs in patients fulfilling the lobular breast cancer-expanded criteria, compared with the 2020 criteria, increased significantly (AUC 0·92 vs 0·88; Z score 3·54; p=0·0004). INTERPRETATION: CDH1 PV/LPVs were positively associated with HDGC-related phenotypes (lobular breast cancer, diffuse gastric cancer, and gastric cancer), and no evidence for a positive association with these phenotypes was found for CDH1 missense variants of unknown significance. CDH1 PV/LPVs occurred often in families with lobular breast cancer who did not fulfil the 2020 HDGC criteria, supporting the expansion of lobular breast cancer-centred criteria. FUNDING: European Reference Network on Genetic Tumour Risk Syndromes, European Regional Development Fund, Fundação para a Ciência e a Tecnologia (Portugal), Cancer Research UK, and European Union's Horizon 2020 research and innovation programme.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Garcia-Pelaez J, Barbosa-Matos R, Lobo S, et al. Genotype-first approach to identify associations between CDH1 germline variants and cancer phenotypes: a multicentre study by the European Reference Network on Genetic Tumour Risk Syndromes. Lancet Oncol. 2022. PMID: 36436516. doi:10.1016/S1470-2045(22)00643-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。